
Feature|Articles|October 30, 2026
Closing the Pediatric Evidence Gap
Author(s)Martine Dehlinger-Kremer, Ph.D.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
Advertisement
Advertisement
Treatment decisions in childhood can have a profound impact on health outcomes later in life. However, clinicians and families often have to make those decisions without evidence generated specifically in children. This uncertainty becomes even greater when the condition is serious, treatment options are limited, and decisions cannot wait.
Related to this article

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.

The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.

Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.

Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, not the original.
Advertisement
Advertisement

